Erasca, Inc.
ERAS
Clasificación en acciones
#3362
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Precio por acción
$14.63
Capitalización bursátil
$5.12B
Cambio (1 día)
7.41%
Cambio (1 año)
494.70%
País
US
Comercio Erasca, Inc. (ERAS)
Categoría
Healthcare
Ganancias de Erasca, Inc. (ERAS)
Ganancias en Jun 2026 TTM: $-287.22M
Secondo gli ultimi rapporti finanziari di Erasca, Inc., gli utili attuali della società sono $-287.22M. Nel 2023, la società ha registrato un utile di $-125.04M, un aumento con respecto a agli utili del 2022, che erano di $-242.81M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Erasca, Inc. desde 2019 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-287.22M | 77.68% |
| 2024 | $-161.65M | 29.28% |
| 2023 | $-125.04M | -48.50% |
| 2022 | $-242.81M | 97.78% |
| 2021 | $-122.76M | 20.76% |
| 2020 | $-101.66M | 744.35% |
| 2019 | $-12.04M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -1,936.52% |
US
|
|
| $-3.09B | 974.77% |
US
|
|
| $-4.02B | 1,298.29% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -779.14% |
NL
|
